Posted: 04/10/2018
ATLANTA--(BUSINESS WIRE)--MNG Laboratories is pleased to announce the signing of several key international distributor agreements in Asia, Latin America and Eastern Europe. MNG now has active distributors representing our extensive menu of over 500 neurogenetic and biochemical tests in Mexico, Hong Kong, Turkey and Chile. Each distributor was chosen for their clinical expertise, excellent customer service, and technical leadership in their respective markets. ?This is just the start of MNG?s expansion strategy for global markets since we br
ATLANTA(BUSINESS WIRE)MNG Laboratories is pleased to announce the signing of several key international distributor agreements in Asia, Latin America and Eastern Europe. MNG now has active distributors representing our extensive menu of over 500 neurogenetic and biochemical tests in Mexico, Hong Kong, Turkey and Chile. Each distributor was chosen for their clinical expertise, excellent customer service, and technical leadership in their respective markets.
?This is just the start of MNG?s expansion strategy for global markets since we brought on dedicated business development talent to address this market opportunity late in 2017,? noted MNG?s President & CEO Terry Conrad. ?We have additional pending agreements in different phases of development across the globe and are active in seeking additional partnerships in the Pharmaceutical, Biotech and University research arenas. MNG has a leadership position in neurogenetic and complex biochemical testing and our products and experience are trusted by research and development interests who are focused in neurology.?
MNG recently launched an updated and innovative approach to exome testing. The MNG Exome? is the only exome test on the market that guarantees 100% coverage of all ClinVar expert panel approved pathogenic variants and detection of uniparental disomy. It also includes mtDNA testing allowing for complete coverage of all coding regions that may be potentially pathogenic. Also, MNG recently launched the MNG Transcriptome? and has been a pioneer in bringing RNA sequencing to the clinical testing market. MNG will soon launch its innovative MNGenome® whole genome sequencing test, made possible by the recent addition of the Illumina NovaSeq platform. The technology upgrade is also expected to further improve our already industry-leading short turnaround times.
About MNG Laboratories MNG Laboratories is an internationally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing. We are committed to a patient-centered testing menu, high-quality diagnostics, and first-in-class reporting driven by our Genome MaNaGer® analysis pipeline. Our Neurogenetic Answers? reporting process helps us stay at the forefront of the evolving genetics field and our team-based approach to data interpretation ensures we provide a reliable, guideline compliant, short list of variants that cause or are likely to cause disease. Our comprehensive approach to diagnostics is accompanied by a team of customer support and scientific personnel available to answer your questions regarding our process, technology, and reports. With over 16 years of neurogenetic experience, and powered by a culture of discovery and advancement, MNG Laboratories delivers results that make a difference for patients and their families.
Links:
Posted: 04/07/2018
MNG is now launching the MNG Xpress? Actionable Epilepsy panel with a standard STAT turnaround time of < 2 weeks at no additional cost and with no additional requisition forms to fill out. Our Actionable Epilepsy panel is now always STAT. You know MNG as your source for Neurogenetic Answers? and we pride ourselves on delivering actionable results you can count on. For patients you suspect have an epilepsy phenotype and you are looking for genetic results that may have an actionable outcome, you need those results STAT. At 69 genes, our MNG X
MNG is now launching the MNG Xpress? Actionable Epilepsy panel with a standard STAT turnaround time of < 2 weeks at no additional cost and with no additional requisition forms to fill out. Our Actionable Epilepsy panel is now always STAT. You know MNG as your source for Neurogenetic Answers? and we pride ourselves on delivering actionable results you can count on. For patients you suspect have an epilepsy phenotype and you are looking for genetic results that may have an actionable outcome, you need those results STAT. At 69 genes, our MNG Xpress? Actionable Epilepsy panel contains a targeted list of epilepsy and seizure related genes - those that are actionable via seizure medications, pharmacological interventions, and dietary changes. For a full list of the actionable genes and therapies in our MNG Xpress? Actionable Eilepsy panel click here. Our complete Epilepsy portfolio contains several flexible options to fit your patient?s needs:
Links:
https://mnglabs.com/introducing-the-mng-xpress-actionable-epilepsy-panel
Posted: 02/01/2018
Now Covering 100% of Expert Approved Pathogenic Variants We are proud to announce that our MNG Exome? now covers all pathogenic variants that are practice guideline and expert panel reviewed in ClinVar. These include variants located in intronic regions that are not covered by standard exome sequencing. In addition to sequencing, we include copy number analysis, mitochondrial genome sequencing + deletion, and heteroplasmy assessment. To learn more about ClinVar guidelines, please click here. New to MNG Exome?: Uniparental Disomy To further
Now Covering 100% of Expert Approved Pathogenic Variants We are proud to announce that our MNG Exome? now covers all pathogenic variants that are practice guideline and expert panel reviewed in ClinVar. These include variants located in intronic regions that are not covered by standard exome sequencing. In addition to sequencing, we include copy number analysis, mitochondrial genome sequencing + deletion, and heteroplasmy assessment. To learn more about ClinVar guidelines, please click here. New to MNG Exome?: Uniparental Disomy To further enhance the comprehensiveness of the MNG Exome?, we have added the first commercially available uniparental disomy detection to our whole exome testing. Uniparental disomy can disrupt parent-specific genomic imprinting, resulting in disorders such as Angelman syndrome and Prader-Willi syndrome. The addition of uniparental disomy detection in the MNG Exome? is essential for improving our ability to finding the answers you need for your patient in one single test.
Links:
